Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976940 | 0.91 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAALDH1A1GAAMEN1 | |
| SCHEMBL2974016 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAALDH1A1GAAMEN1 | |
| SCHEMBL2968993 | 0.82 | PRMT5 (0.39) | SMN1; SMN2LMNAALDH1A1MAPTTSHR | |
| SCHEMBL2973039 | 0.82 | LMNA (0.46) | SMN1; SMN2LMNAALDH1A1GAAMEN1 | |
| SCHEMBL2968995 | 0.81 | PRMT5 (0.38) | LMNAALDH1A1TSHR | |
| SCHEMBL5673099 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAALDH1A1GAAMEN1 | |
| SCHEMBL2977058 | 0.80 | GSTP1 (0.39) | SMN1; SMN2ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3582399 | 0.77 | ALDH1A1 (0.38) | SMN1; SMN2LMNAALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL15574003 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAALDH1A1GAAMEN1 | |
| SCHEMBL15573295 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAALDH1A1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776924-B2 | Nitroaniline-based alkylating agents and their use as prodrugs | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-08-17 | — | — | US | disclosed |
| EP-1558568-A4 | NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS | AUCKLAND UNISERVICES LTD (NZ) | 2006-10-18 | — | — | EP | disclosed |
| US-20050256191-A1 | Nitroaniline-based alkylating agents and their use as prodrugs | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-11-17 | — | — | US | disclosed |
| EP-1558568-A1 | NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS | Auckland Uniservices Limited (NZ) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004033415-A1 | NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256191-A1 | Nitroaniline-based alkylating agents and their use as prodrugs | IDH3A, HIF1AN, IDH1 | SMN1; SMN2 2843/4885LMNA 3875/4885ALDH1A1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.